RAPT Therapeutics(US:RAPT)2025-11-06 13:02Financial Performance - Net loss for Q3 2025 was $17.6 million, a decrease of 4.4% from $18.4 million in Q3 2024[7] - Net loss for the nine months ended September 30, 2025 was $52.4 million, significantly reduced from $76.6 million for the same period in 2024[12] Expenses - Research and development expenses for Q3 2025 were $12.0 million, down 10% from $13.3 million in Q3 2024[10] - General and administrative expenses for Q3 2025 increased to $7.3 million, up 13.9% from $6.4 million in Q3 2024[11] Cash Position - Cash and cash equivalents and marketable securities as of September 30, 2025 totaled $157.3 million[15] - The current cash balance is projected to fund operations to mid-2028, including planned Phase 3 studies of ozureprubart in CSU[9] Capital Raising - The company completed a public offering of 8,333,334 shares at $30.00 per share, raising gross proceeds of $250 million[9] Clinical Trials - Positive topline data from the Phase 2 trial in chronic spontaneous urticaria showed ozureprubart had comparable efficacy and safety to omalizumab[8] - The company plans to report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma and provide additional details from the CSU trial at a medical meeting next year[3] - The FDA has cleared the IND application for a Phase 2b trial of ozureprubart in food allergy, which was initiated in October 2025[9]